Kelun-Biotech's Lung Cancer Drug Combination Succeeds in Phase III Trial

Kelun-Biotech announced positive results from its Phase III clinical study for sacituzumab tirumotecan (sac-TMT) combined with pembrolizumab. The trial, focusing on first-line treatment for PD-L1-negative non-squamous non-small cell lung cancer, successfully met its primary endpoint. This outcome supports the potential expansion of this combination therapy for a broader population of lung cancer patients.